HEC5971 - Pharmaceutical economics - 2018

6 points, SCA Band 3, 0.125 EFTSL

Postgraduate - Unit

Refer to the specific census and withdrawal dates for the semester(s) in which this unit is offered.

Faculty

Business and Economics

Organisational Unit

Centre for Health Economics

Coordinator(s)

Dr Silva Zavarsek

Unit guides

Offered

Clayton

Prohibitions

ECX9710

Synopsis

The economics of the pharmaceutical industry including the market for pharmaceuticals and its regulation internationally and in Australia. Principles of economic evaluation of the costs and outcomes of pharmaceutical products, and provides a guide to best practice with particular emphasis on clinical trials and protocol design.

Outcomes

The learning goals associated with this unit are to:

  1. investigate the role of economic analysis in the pharmaceutical industry
  2. understand the structure of the pharmaceutical industry and the inter-relationship between the nature of the product, market structure and government regulation
  3. understand the impact of government intervention in the pharmaceutical industry including alternative regulatory regimes
  4. explain the role of economic evaluation in promoting the efficient use of drugs
  5. perform an economic analysis of drugs alongside clinical trials, including techniques of health outcome measurement.

Assessment

Within semester assessment: 70% + Examination: 30%

Workload requirements

Minimum total expected workload to achieve the learning outcomes for this unit is 144 hours per semester typically comprising a mixture of scheduled learning activities and independent study. Independent study may include associated readings, assessment and preparation for scheduled activities. The unit requires on average three/four hours of scheduled activities per week. Scheduled activities may include a combination of teacher directed learning, peer directed learning and online engagement.

See also Unit timetable information